On January 3, 2018 GeneCentric Therapeutics, Inc. reported a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC) (Press release, GeneCentric Therapeutics, JAN 3, 2018, View Source [SID1234522885]). As part of the research collaboration, GeneCentric will apply its lung cancer subtyping profilers (LSP) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes. Financial terms were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
GeneCentric’s proprietary core technology, CSP, identifies biologic subtypes of cancer through an integrated analysis of tumor genomics. The subtypes, which combine gene expression data with disease-related molecular pathways and immune cell expression have potential to function as universal biomarkers of drug response and enable more precision drug development. GeneCentric’s Lung Cancer Profilers (LSP 210 and LSP 220) define molecular subtypes of the two most common forms of NSCLC, adenocarcinoma and squamous cell carcinoma. Published studies have demonstrated that the subtypes, while indistinguishable by standard morphology, have different genetic, molecular and clinical attributes, and immune profiles that may drive drug response.
"G1T38 is a novel and promising targeted therapeutic with potential in many cancers," said Myla Lai-Goldman, M.D., CEO of GeneCentric. "This collaboration could identify subtypes of lung cancer where the compound is most likely to be efficacious."